BD PharmingenTM Purified Rat Anti-Mouse IL-4

Description

Expression of IL-4 by MiCK-2 positive control cells. MiCK-2 positive control cells Cat. No. 554653 were stained with 0.125 mug of FITC-conjugated rat anti-mouse IL-4 antibody by using the BD Pharmingen staining protocol see left panel . To demonstrate specificity of staining, the binding of FITC-BVD4-1D11 was blocked by the preincubation of the conjugated antibody with recombinant mouse IL-4 0.25 mug, Cat. No. 550067; see middle panel , and by preincubation of the fixed/permeabilized cells with unlabeled BVD4-1D11 antibody 5 mug, Cat. No. 554386; see right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabeled antibody blocking specificity controls. Expression of IL-4 by MiCK-2 positive control cells. MiCK-2 positive control cells Cat. No. 554653 were stained with 0.125 mug of FITC-conjugated rat anti-mouse IL-4 antibody by using the BD Pharmingen staining protocol see left panel . To demonstrate specificity of staining, the binding of FITC-BVD4-1D11 was blocked by the preincubation of the conjugated antibody with recombinant mouse IL-4 0.25 mug, Cat. No. 550067; see middle panel , and by preincubation of the fixed/permeabilized cells with unlabeled BVD4-1D11 antibody 5 mug, Cat. No. 554386; see right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabeled antibody blocking specificity controls. Expression of IL-4 by MiCK-2 positive control cells. MiCK-2 positive control cells Cat. No. 554653 were stained with 0.125 mug of FITC-conjugated rat anti-mouse IL-4 antibody by using the BD Pharmingen staining protocol see left panel . To demonstrate specificity of staining, the binding of FITC-BVD4-1D11 was blocked by the preincubation of the conjugated antibody with recombinant mouse IL-4 0.25 mug, Cat. No. 550067; see middle panel , and by preincubation of the fixed/permeabilized cells with unlabeled BVD4-1D11 antibody 5 mug, Cat. No. 554386; see right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabeled antibody blocking specificity controls. Show More Expression of IL-4 by MiCK-2 positive control cells. MiCK-2 positive control cells Cat. No. 554653 were stained with 0.125 mug of FITC-conjugated rat anti-mouse IL-4 antibody by using the BD Pharmingen staining protocol see left panel . To demonstrate specificity of staining, the binding of FITC-BVD4-1D11 was blocked by the preincubation of the conjugated antibody with recombinant mouse IL-4 0.25 mug, Cat. No. 550067; see middle panel , and by preincubation of the fixed/permeabilized cells with unlabeled BVD4-1D11 antibody 5 mug, Cat. No. 554386; see right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabeled antibody blocking specificity controls. Show More Expression of IL-4 by MiCK-2 positive control cells. MiCK-2 positive control cells Cat. No. 554653 were stained with 0.125 mug of FITC-conjugated rat anti-mouse IL-4 antibody by using the BD Pharmingen staining protocol see left panel . To demonstrate specificity of staining, the binding of FITC-BVD4-1D11 was blocked by the preincubation of the conjugated antibody with recombinant mouse IL-4 0.25 mug, Cat. No. 550067; see middle panel , and by preincubation of the fixed/permeabilized cells with unlabeled BVD4-1D11 antibody 5 mug, Cat. No. 554386; see right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabeled antibody blocking specificity controls. Expression of IL-4 by MiCK-2 positive control cells. MiCK-2 positive control cells Cat. No. 554653 were stained with 0.125 mug of FITC-conjugated rat anti-mouse IL-4 antibody by using the BD Pharmingen staining protocol see left panel . To demonstrate specificity of staining, the binding of FITC-BVD4-1D11 was blocked by the preincubation of the conjugated antibody with recombinant mouse IL-4 0.25 mug, Cat. No. 550067; see middle panel , and by preincubation of the fixed/permeabilized cells with unlabeled BVD4-1D11 antibody 5 mug, Cat. No. 554386; see right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabeled antibody blocking specificity controls.